This drug may reduce 'bad' cholesterol by half in high risk patients

Gallery

MORE...

Sports

Asian Games medallist Jyothi Yarraji to train in Spain ahead of Paris Olympics

Jyothi Yarraji, who won a silver medal in the 100m hurdles at the Hangzhou Asian Games, wi

Lione Messi said Retirement not on my mind

Indian Wells: Alcaraz, Swiatek win titles

African footballer chased and thrashed away in Kerala; reports

Hockey India announce core probable group for men's national camp in Bhubaneswar

Interim Budget: Large number of institutions of higher learning set up, highest ever medal tally in games reflects high confidence level, says FM

MORE...

This drug may reduce 'bad' cholesterol by half in high risk patients

Last Updated : 17 Nov 2020 03:41:56 PM IST

File photo

The investigational drug 'evinacumab' reduces low-density lipoprotein (LDL) 'bad' cholesterol by 50 per cent in patients with severe hypercholesterolemia, researchers said.

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood, the study, published in the New England Journal of Medicine, reported.

According to the reseearchers, evinacumab is a fully human monoclonal antibody that works through a different mechanism than existing drugs to bring dangerously high cholesterol to normal levels.

"Our study assessing the safety and efficacy of evinacumab shows that it can lower LDL cholesterol by half in patients unable to attain target guidelines despite maximally tolerated lipid lowering therapy," said study author Robert Rosenson from Mount Sinai Hospital in the US.

Evinacumab is a fully human monoclonal antibody that inhibits angiopoietin like protein 3 (ANGPLT3) and lowers LDL cholesterol through an LDL receptor independent pathway.

Genetic studies have shown that people who are missing or have low levels of ANGPTL3 are known to have very low lifelong levels of LDL cholesterol and rarely suffer from atherosclerotic cardiovascular disease.

The phase two, double-blinded, placebo-controlled study of evinacumab included 272 patients with primary high cholesterol including a majority having a diagnosis of heterozygous familial hypercholesterolemia (HeFH).

HeFH is an inherited form of hypercholesterolemia most often caused by mutations in the LDL receptor gene.

The research team found that subcutaneous administration of the agent at 450 mg weekly resulted in LDL cholesterol lowering of 56 per cent, and 52.9 per cent at 300 mg weekly compared to the placebo group.

With monthly intravenous administration of evinacumab at 15 mg/kg, LDL cholesterol reduction was 50.5 per cent compared to the placebo group.

"Our study demonstrates that a regimen of either subcutaneous or intravenous evinacumab can have a significant impact on LDL cholesterol," said Rosenson.

"If approved for use in this setting, evinacumab could potentially arm cardiologists with a major new add-on therapy to bring patients with HeFH to or closer to their cholesterol-lowering goal," Rosenson noted.